Abstract MP54: Pro-resolving Lipid Mediators Ameliorate Endothelium Dysfunction In Arteries From Hypertensive Rats Meeting Abstract (Web of Science)

abstract

  • Resolution of inflammation is an active phenomenon to switch off the inflammatory processes andfacilitate the return to homeostasis. Increasing the levels of pro-resolving lipid mediators topromote the resolution of inflammation is emerging as a novel therapeutic approach. Arachidonicacid (AA) and docosahexaenoic acid (DHA) are substrates to produce the pro-resolving lipidmediators lipoxin A4 (LXA4) and resolvin D1 (RvD1), respectively. However, it is unknown if thesemediators can ameliorate dysfunction in arteries from hypertensive animals. Therefore, wehypothesized that pro-resolving lipid mediators decrease acetylcholine-induced contractions inarteries from spontaneously hypertensive rats (SHR). Mesenteric resistance arteries from maleSHR and Wistar Kyoto (WKY) (14-weeks old, n=6-8) were used for vascular function via wiremyograph. MRA were incubated with either RvD1 or LXA4 (10 nM, 1 hour) or vehicle prior toconcentration response curves to acetylcholine or phenylephrine (1 nM - 3 μM). We alsoperformed lipidomic analysis on plasma from WKY and SHR. As expected, low concentrations (≤100 nM) of acetylcholine induced relaxation in arteries from both groups, however highconcentrations (≥ 1 μM) of acetylcholine induced contraction in arteries from SHR, but not in WKY[Relaxation to acetylcholine [Area Under the curve (AUC)]: WKY: 396.6 ± 17.7 vs. SHR-control:296.0 ± 26.7*, t-test *vs. WKY, p=0.03). Treatment with the mediators did not change relaxationin arteries from WKY (AUC: Vehicle: 396.6 ±17.7 vs. RvD1: 402.8 ± 18.0; LXA4: 399.0 ± 18.4,p>0.05). However, incubation with RvD1 or LXA4 reduced acetylcholine induced-contraction inarteries from SHR (AUC: Vehicle: 296.0 ± 26.7 vs. RvD1: 372.5 ± 18.5*; LXA4: 376.8 ± 23.6*, t-test *vs. vehicle, p<0.05). Lipidomic analysis showed that precursors for pro-resolving lipidmediators are decreased in SHR [DHA (pmol/mL): WKY: 5637.5 ± 275.3 vs. SHR: 4509.2 ±453.9*, AA: WKY:16018.3 ± 351.3 vs. SHR: 13928.5 ± 959.5 *vs. WKY, p<0.05]. Overall, theseresults suggest that resolution of inflammation and the pro-resolving lipid mediators, RvD1 orLXA4, may be used as a new therapeutic tool to improve vascular function in hypertension.

authors

  • Edwards, Jonnelle M
  • Waigi, Emily W
  • Bearss, Nicole
  • Joe, Bina
  • McCarthy, Cameron G
  • Wenceslau, Camilla F

publication date

  • 2021

webpage

published in

volume

  • 78

issue

  • Suppl_1